Your browser is no longer supported. Please, upgrade your browser.
Settings
NVCR NovoCure Limited daily Stock Chart
NVCR [NASD]
NovoCure Limited
Index- P/E43980.00 EPS (ttm)0.00 Insider Own1.60% Shs Outstand100.72M Perf Week-2.24%
Market Cap13.04B Forward P/E429.77 EPS next Y0.31 Insider Trans-25.50% Shs Float84.43M Perf Month25.53%
Income0.50M PEG- EPS next Q0.04 Inst Own69.40% Short Float6.32% Perf Quarter97.40%
Sales409.00M P/S31.87 EPS this Y89.30% Inst Trans0.17% Short Ratio5.37 Perf Half Y82.44%
Book/sh2.66 P/B49.60 EPS next Y107.43% ROA2.40% Target Price112.00 Perf Year75.36%
Cash/sh3.51 P/C37.60 EPS next 5Y- ROE5.10% 52W Range53.40 - 140.89 Perf YTD56.57%
Dividend- P/FCF609.14 EPS past 5Y40.20% ROI0.20% 52W High-7.74% Beta1.43
Dividend %- Quick Ratio5.40 Sales past 5Y86.70% Gross Margin76.10% 52W Low143.41% ATR5.71
Employees782 Current Ratio5.70 Sales Q/Q33.70% Oper. Margin1.80% RSI (14)65.08 Volatility3.61% 4.24%
OptionableYes Debt/Eq0.56 EPS Q/Q216.60% Profit Margin2.90% Rel Volume0.78 Prev Close131.94
ShortableYes LT Debt/Eq0.56 EarningsOct 29 BMO Payout0.00% Avg Volume992.47K Price129.98
Recom2.80 SMA206.37% SMA5029.09% SMA20065.24% Volume557,095 Change-1.49%
Sep-23-20Initiated Northland Capital Outperform $200
Sep-18-20Downgrade Wells Fargo Overweight → Equal Weight $116
Sep-17-20Downgrade Truist Buy → Hold $108
Jun-01-20Resumed Oppenheimer Perform
May-01-20Downgrade Oppenheimer Outperform → Perform
Apr-09-20Downgrade Evercore ISI In-line → Underperform $58
Mar-05-20Upgrade Wells Fargo Equal Weight → Overweight $85 → $90
Jan-02-20Downgrade Evercore ISI Outperform → In-line $84 → $90
Jul-29-19Upgrade SunTrust Hold → Buy
Jul-26-19Downgrade Wedbush Outperform → Neutral $57 → $80
Jul-26-19Downgrade JP Morgan Overweight → Neutral $61 → $79
Mar-20-19Initiated SunTrust Hold
Nov-02-18Downgrade Wells Fargo Outperform → Market Perform
Jul-16-18Initiated Evercore ISI Outperform $46
Apr-18-18Reiterated Mizuho Buy $28 → $32
Feb-23-18Reiterated Mizuho Buy $25 → $28
May-24-17Upgrade Wells Fargo Market Perform → Outperform
Jul-29-16Reiterated Wedbush Outperform $30 → $20
Jan-19-16Initiated Barclays Underweight $16
Dec-02-15Initiated Deutsche Bank Hold $28
Oct-09-20 08:23AM  
Oct-07-20 12:11PM  
Oct-05-20 03:27PM  
Oct-02-20 11:30AM  
08:56AM  
Sep-29-20 07:30AM  
Sep-28-20 08:43PM  
Sep-25-20 04:00PM  
Sep-24-20 12:41PM  
Sep-23-20 11:25AM  
Sep-09-20 03:12PM  
Sep-04-20 07:30AM  
Aug-29-20 08:00AM  
Aug-24-20 03:29PM  
Aug-13-20 11:37AM  
08:30AM  
Jul-30-20 09:01PM  
06:00AM  
Jul-28-20 07:30AM  
Jul-24-20 09:37PM  
Jul-23-20 12:33PM  
12:00PM  
Jul-22-20 07:30AM  
Jul-15-20 04:38PM  
09:10AM  
07:30AM  
Jul-12-20 08:54PM  
Jul-08-20 07:30AM  
06:00AM  
Jul-07-20 07:30AM  
Jul-01-20 07:30AM  
Jun-18-20 12:02PM  
Jun-08-20 01:07AM  
Jun-02-20 07:30AM  
May-13-20 10:10AM  
May-05-20 11:30PM  
May-04-20 10:21AM  
May-02-20 11:30AM  
Apr-30-20 04:05PM  
07:30AM  
06:00AM  
Apr-27-20 07:30AM  
Apr-23-20 12:32PM  
Apr-07-20 03:07PM  
09:00AM  
Apr-03-20 07:30AM  
Mar-23-20 12:24AM  
Mar-20-20 09:16AM  
Mar-19-20 07:30AM  
Mar-12-20 07:30AM  
Mar-10-20 03:18AM  
Feb-27-20 07:30AM  
06:00AM  
Feb-20-20 12:31PM  
Feb-11-20 08:54AM  
Feb-05-20 09:15AM  
Feb-04-20 02:56PM  
Jan-29-20 09:15AM  
Jan-23-20 07:24AM  
Jan-21-20 04:35PM  
07:40AM  
Jan-17-20 10:17AM  
Jan-16-20 04:45PM  
Jan-13-20 06:00AM  
Jan-09-20 07:30AM  
Jan-03-20 08:40AM  
Dec-26-19 07:30AM  
Dec-08-19 07:11PM  
Dec-04-19 04:05PM  
09:55AM  
Dec-02-19 07:30AM  
05:00AM  
Nov-26-19 07:30AM  
07:30AM  
Nov-20-19 07:30AM  
Nov-04-19 09:35AM  
Nov-01-19 11:10AM  
Oct-31-19 07:35AM  
06:00AM  
06:00AM  
Oct-27-19 10:08AM  
Oct-24-19 10:32AM  
Oct-18-19 07:35AM  
Oct-16-19 10:31AM  
Oct-14-19 06:13PM  
01:31PM  
Oct-01-19 07:30AM  
Sep-13-19 06:59PM  
Sep-11-19 07:15PM  
Sep-09-19 11:34AM  
09:25AM  
Sep-04-19 09:44AM  
Aug-30-19 06:54PM  
Aug-29-19 08:50AM  
Aug-27-19 11:37AM  
Aug-14-19 05:38AM  
Aug-13-19 07:01AM  
Aug-12-19 07:30AM  
07:30AM  
Aug-07-19 11:17AM  
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and NovoTTF-100L, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products that are in Phase 2 pilot and Phase 3 pivotal trials for brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Weinberg UriChief Science OfficerSep 25Option Exercise9.6215,250146,75036,347Sep 28 06:13 PM
Weinberg UriChief Science OfficerSep 25Sale103.3515,2501,576,08827,597Sep 28 06:13 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerSep 18Option Exercise7.488,26261,800150,869Sep 21 04:16 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerSep 18Sale109.218,262902,294142,607Sep 21 04:16 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerSep 17Option Exercise7.4812,50093,500155,107Sep 18 04:37 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerSep 17Sale108.6012,5001,357,556142,607Sep 18 04:37 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerSep 16Option Exercise7.2922,012160,369155,107Sep 18 04:37 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerSep 16Sale107.3522,0122,363,014142,607Sep 18 04:37 PM
LEUNG GABRIELDirectorSep 15Option Exercise7.489,56571,54679,437Sep 16 05:27 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerSep 15Option Exercise7.3750,868374,868155,975Sep 16 05:24 PM
Danziger AsafChief Executive OfficerSep 15Option Exercise22.00103,0002,266,000300,632Sep 17 04:32 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerSep 15Sale103.2750,8685,253,018142,607Sep 16 05:24 PM
LEUNG GABRIELDirectorSep 15Sale100.009,565956,50072,045Sep 16 05:27 PM
Danziger AsafChief Executive OfficerSep 15Sale99.00103,00010,197,000197,632Sep 17 04:32 PM
LEUNG GABRIELDirectorSep 14Option Exercise7.4810,00074,80082,045Sep 16 05:27 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerSep 14Option Exercise7.0325,000175,750155,107Sep 16 05:24 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerSep 14Sale98.0125,0002,450,213142,607Sep 16 05:24 PM
LEUNG GABRIELDirectorSep 14Sale95.0010,000950,00072,045Sep 16 05:27 PM
LEUNG GABRIELDirectorSep 10Option Exercise7.4810,00074,80082,045Sep 11 04:15 PM
LEUNG GABRIELDirectorSep 10Sale90.0010,000900,00072,045Sep 11 04:15 PM
LEUNG GABRIELDirectorSep 09Option Exercise7.039,11464,07181,159Sep 11 04:15 PM
LEUNG GABRIELDirectorSep 09Sale85.409,114778,29372,045Sep 11 04:15 PM
Shah PriteshChief Commercial OfficerSep 09Sale85.4128,3212,418,88170,465Sep 11 04:19 PM
LEUNG GABRIELDirectorSep 02Option Exercise7.0310070372,145Sep 04 04:17 PM
LEUNG GABRIELDirectorSep 02Sale85.001008,50072,045Sep 04 04:17 PM
LEUNG GABRIELDirectorAug 25Option Exercise7.037,11249,99779,157Aug 27 04:13 PM
LEUNG GABRIELDirectorAug 25Sale80.137,112569,89272,045Aug 27 04:13 PM
Shah PriteshChief Commercial OfficerAug 04Sale76.812,048157,307101,018Aug 05 04:13 PM
Shah PriteshChief Commercial OfficerAug 03Sale76.411,669127,522103,066Aug 05 04:13 PM
Benaim ElyChief Medical OfficerAug 03Sale76.0666050,20029,356Aug 05 04:11 PM
Shah PriteshChief Commercial OfficerJul 31Option Exercise76.173,717283,124104,735Aug 03 05:39 PM
Benaim ElyChief Medical OfficerJul 31Sale76.3934126,04830,016Aug 03 05:53 PM
DOYLE WILLIAM FExecutive ChairmanJul 31Sale76.3989668,444649,062Aug 03 05:51 PM
LEUNG GABRIELDirectorJul 30Option Exercise7.037,11249,99779,157Aug 03 05:45 PM
LEUNG GABRIELDirectorJul 30Sale75.007,112533,40072,045Aug 03 05:45 PM
Ambrogi Michael J.Chief Operating OfficerJul 22Option Exercise18.4042,972790,640251,639Jul 23 07:43 PM
LEUNG GABRIELDirectorJul 22Option Exercise7.039,50066,78581,545Jul 23 07:32 PM
Ambrogi Michael J.Chief Operating OfficerJul 22Sale67.0242,9722,879,966220,867Jul 23 07:43 PM
LEUNG GABRIELDirectorJul 22Sale67.039,500636,79772,045Jul 23 07:32 PM
Ambrogi Michael J.Chief Operating OfficerJul 21Option Exercise20.273,32167,332223,888Jul 23 07:43 PM
LEUNG GABRIELDirectorJul 21Option Exercise7.035003,51572,545Jul 23 07:32 PM
Ambrogi Michael J.Chief Operating OfficerJul 21Sale65.063,321216,072220,867Jul 23 07:43 PM
LEUNG GABRIELDirectorJul 21Sale65.0750032,53772,045Jul 23 07:32 PM
Benaim ElyChief Medical OfficerMay 12Sale64.782,595168,10412,616May 14 04:14 PM
DOYLE WILLIAM FExecutive ChairmanMay 11Sale63.7331,3321,996,726649,958May 12 04:13 PM
Benaim ElyChief Medical OfficerMay 11Sale63.731,611102,66615,211May 12 04:22 PM
DOYLE WILLIAM FExecutive ChairmanMay 08Option Exercise63.8458,7673,751,685713,193May 11 04:17 PM
Benaim ElyChief Medical OfficerMay 08Option Exercise63.844,206268,51116,822May 12 04:22 PM
Weinberg UriChief Science OfficerMay 08Option Exercise63.841,40289,50425,629May 11 04:22 PM
DOYLE WILLIAM FExecutive ChairmanMay 08Sale63.5031,9032,025,872681,290May 11 04:17 PM
DOYLE WILLIAM FExecutive ChairmanMay 07Option Exercise64.7758,7683,806,403685,419May 11 04:17 PM
DOYLE WILLIAM FExecutive ChairmanMay 07Sale64.7430,9932,006,518654,426May 11 04:17 PM
DOYLE WILLIAM FExecutive ChairmanMay 06Option Exercise64.1558,7683,769,967626,651May 07 04:41 PM
DOYLE WILLIAM FExecutive ChairmanMay 06Sale64.2729,8811,920,452567,883May 07 04:41 PM
DOYLE WILLIAM FExecutive ChairmanMay 05Option Exercise61.4058,7683,608,355628,047May 07 04:41 PM
Shah PriteshChief Commercial OfficerMay 05Sale62.201,14971,468100,693May 07 04:48 PM
DOYLE WILLIAM FExecutive ChairmanMay 05Sale62.4730,2831,891,718597,764May 07 04:41 PM
DOYLE WILLIAM FExecutive ChairmanMay 04Option Exercise60.4858,7683,554,289569,279May 06 05:52 PM
Shah PriteshChief Commercial OfficerMay 04Sale60.081,18471,134101,842May 05 04:32 PM
Shah PriteshChief Commercial OfficerMay 01Option Exercise65.802,333153,511103,026May 05 04:32 PM
Ambrogi Michael J.Chief Operating OfficerApr 14Option Exercise7.1535,745255,577256,612Apr 15 05:03 PM
Ambrogi Michael J.Chief Operating OfficerApr 14Sale71.0027,5191,953,970220,867Apr 15 05:03 PM
Ambrogi Michael J.Chief Operating OfficerApr 13Option Exercise7.1522,755162,698243,622Apr 15 05:03 PM
Ambrogi Michael J.Chief Operating OfficerApr 13Sale69.3230,9812,147,594220,867Apr 15 05:03 PM
Shah PriteshChief Commercial OfficerMar 06Option Exercise7.4817,500130,900103,938Mar 10 04:20 PM
DOYLE WILLIAM FExecutive ChairmanMar 06Sale69.534,320300,387510,511Mar 10 04:18 PM
Longsworth Todd ChristopherGeneral CounselMar 06Sale69.532,499173,76586,753Mar 10 04:15 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerMar 06Sale69.533,123217,155140,386Mar 10 04:13 PM
Shah PriteshChief Commercial OfficerMar 06Sale66.766,151410,62286,438Mar 10 04:20 PM
Ambrogi Michael J.Chief Operating OfficerMar 06Sale69.532,274158,120220,867Mar 10 04:22 PM
Shah PriteshChief Commercial OfficerMar 02Sale72.971,485108,36067,721Mar 05 04:47 PM
Longsworth Todd ChristopherGeneral CounselFeb 28Sale72.222,643190,86470,032Mar 02 05:11 PM
DOYLE WILLIAM FExecutive ChairmanFeb 28Sale72.223,893281,133514,831Mar 02 05:13 PM
Ambrogi Michael J.Chief Operating OfficerFeb 28Sale72.222,673193,031208,726Mar 02 05:17 PM
Shah PriteshChief Commercial OfficerFeb 28Sale72.221,601115,61669,206Mar 02 05:22 PM
Shah PriteshChief Commercial OfficerFeb 27Option Exercise79.453,086245,18370,807Mar 02 05:22 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerFeb 27Option Exercise0.007,7160119,484Mar 02 05:18 PM
Ambrogi Michael J.Chief Operating OfficerFeb 27Option Exercise79.456,173490,445211,399Mar 02 05:17 PM
Danziger AsafChief Executive OfficerFeb 27Option Exercise79.459,259735,628197,348Mar 02 05:15 PM
DOYLE WILLIAM FExecutive ChairmanFeb 27Option Exercise79.459,259735,628518,724Mar 02 05:13 PM
Longsworth Todd ChristopherGeneral CounselFeb 27Option Exercise79.455,556441,42472,675Mar 02 05:11 PM
Shah PriteshChief Commercial OfficerFeb 26Sale79.397,932629,72567,721Feb 28 04:41 PM
Ambrogi Michael J.Chief Operating OfficerFeb 25Sale81.1611,647945,224205,226Feb 26 05:10 PM
Longsworth Todd ChristopherGeneral CounselFeb 25Sale81.168,482688,36567,119Feb 26 05:14 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerFeb 25Sale81.1618,9081,534,498111,768Feb 26 05:17 PM
Shah PriteshChief Commercial OfficerFeb 25Sale81.165,067411,21775,653Feb 28 04:41 PM
Danziger AsafChief Executive OfficerFeb 24Option Exercise88.2653,3334,707,171188,089Feb 26 05:19 PM
Shah PriteshChief Commercial OfficerFeb 24Option Exercise88.2612,9991,147,29280,720Feb 26 05:18 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerFeb 24Option Exercise88.2643,3333,824,571130,676Feb 26 05:17 PM
Longsworth Todd ChristopherGeneral CounselFeb 24Option Exercise88.2621,6661,912,24175,601Feb 26 05:14 PM
Ambrogi Michael J.Chief Operating OfficerFeb 24Option Exercise88.2631,1992,753,624216,873Feb 26 05:10 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerJan 22Option Exercise7.032,91520,49288,858Jan 24 07:11 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerJan 22Sale98.142,915286,08487,343Jan 24 07:11 PM
DOYLE WILLIAM FExecutive ChairmanJan 17Sale95.00133,77712,708,815509,465Jan 22 04:19 PM
PHILLIPS CHARLES G IIIDirectorDec 02Sale88.116,145541,4483,359Dec 04 04:23 PM
LEUNG GABRIELDirectorNov 25Option Exercise7.0320,000140,60089,504Nov 26 04:23 PM
Danziger AsafChief Executive OfficerNov 25Option Exercise22.00103,0002,266,000237,601Nov 26 04:28 PM
LEUNG GABRIELDirectorNov 25Sale95.0020,0001,900,00069,504Nov 26 04:23 PM
Danziger AsafChief Executive OfficerNov 25Sale95.00103,0009,785,000134,601Nov 26 04:28 PM
DOYLE WILLIAM FExecutive ChairmanNov 25Sale96.0416,2231,558,057643,242Nov 26 04:29 PM
NERV Minerva Neurosciences, Inc. daily Stock Chart
NERV [NASD]
Minerva Neurosciences, Inc.
Index- P/E- EPS (ttm)-0.70 Insider Own0.10% Shs Outstand39.48M Perf Week-8.29%
Market Cap133.05M Forward P/E- EPS next Y-0.81 Insider Trans-3.13% Shs Float35.75M Perf Month-6.14%
Income-26.50M PEG- EPS next Q-0.23 Inst Own68.00% Short Float9.91% Perf Quarter-11.08%
Sales41.20M P/S3.23 EPS this Y-43.10% Inst Trans0.33% Short Ratio4.63 Perf Half Y-55.79%
Book/sh1.44 P/B2.23 EPS next Y-8000.00% ROA-32.80% Target Price- Perf Year-22.84%
Cash/sh0.85 P/C3.77 EPS next 5Y- ROE-66.70% 52W Range1.81 - 15.22 Perf YTD-54.85%
Dividend- P/FCF- EPS past 5Y16.20% ROI- 52W High-78.67% Beta1.51
Dividend %- Quick Ratio4.80 Sales past 5Y- Gross Margin- 52W Low79.28% ATR0.19
Employees13 Current Ratio4.80 Sales Q/Q- Oper. Margin- RSI (14)47.74 Volatility4.94% 5.37%
OptionableYes Debt/Eq0.00 EPS Q/Q329.30% Profit Margin-64.40% Rel Volume0.28 Prev Close3.21
ShortableYes LT Debt/Eq0.00 EarningsAug 03 BMO Payout- Avg Volume764.20K Price3.24
Recom2.00 SMA20-1.59% SMA50-0.65% SMA200-44.55% Volume152,444 Change1.09%
Jun-08-20Reiterated H.C. Wainwright Buy $20 → $10
May-14-20Initiated BTIG Research Buy $23
Oct-02-19Reiterated Chardan Capital Markets Buy $17
Sep-25-19Initiated Chardan Capital Markets Buy $17
Sep-18-19Initiated William Blair Outperform
May-31-19Initiated H.C. Wainwright Buy
Sep-01-17Initiated Citigroup Buy $11
Mar-06-17Resumed Jefferies Buy $17
May-12-16Resumed Jefferies Buy
Oct-05-20 03:00PM  
Sep-14-20 10:20AM  
Sep-09-20 08:30AM  
Sep-02-20 08:30AM  
Aug-13-20 08:00AM  
Aug-05-20 09:30AM  
Aug-03-20 07:01PM  
07:30AM  
Jul-27-20 08:00AM  
Jul-01-20 08:00AM  
Jun-27-20 03:17PM  
Jun-22-20 08:47AM  
Jun-05-20 09:05AM  
Jun-02-20 09:00AM  
Jun-01-20 02:15PM  
08:00AM  
May-31-20 07:50AM  
May-29-20 04:50PM  
11:48AM  
10:31AM  
10:15AM  
09:20AM  
May-27-20 09:40AM  
May-26-20 11:41AM  
10:43AM  
May-25-20 06:41PM  
May-11-20 09:52AM  
08:41AM  
May-08-20 07:55AM  
May-04-20 06:30PM  
07:30AM  
Apr-27-20 08:30AM  
Apr-20-20 01:40PM  
Mar-28-20 02:49AM  
Mar-24-20 08:30AM  
Mar-19-20 10:50AM  
Mar-12-20 03:15PM  
Mar-09-20 07:30AM  
06:30AM  
Mar-02-20 08:30AM  
Feb-28-20 08:30AM  
Feb-17-20 11:15AM  
Feb-05-20 08:00AM  
Jan-06-20 08:00AM  
Dec-24-19 07:06AM  
Dec-19-19 03:07PM  
09:35AM  
07:52AM  
Dec-18-19 04:05PM  
Dec-17-19 07:47PM  
08:29AM  
Dec-04-19 04:05PM  
Nov-21-19 12:21AM  
Nov-14-19 08:30AM  
Nov-11-19 12:10AM  
Nov-04-19 07:30AM  
Oct-28-19 08:30AM  
Oct-18-19 09:37AM  
Oct-02-19 08:47AM  
Oct-01-19 04:43PM  
09:23AM  
08:49AM  
07:30AM  
Sep-26-19 04:10PM  
Sep-24-19 09:00AM  
Sep-23-19 11:46AM  
Sep-20-19 09:10AM  
Sep-19-19 09:38AM  
Sep-03-19 10:53AM  
Aug-09-19 03:08AM  
Aug-05-19 03:59PM  
07:30AM  
Jul-29-19 08:00AM  
Jul-04-19 11:36AM  
Jun-28-19 03:19PM  
Jun-24-19 11:00AM  
08:12AM  
07:30AM  
Jun-23-19 05:30PM  
Jun-12-19 08:30AM  
May-29-19 08:30AM  
May-13-19 11:01AM  
08:15AM  
May-10-19 09:29AM  
May-07-19 02:06PM  
May-06-19 12:00PM  
07:35AM  
07:30AM  
Apr-29-19 08:30AM  
Apr-11-19 08:30AM  
Mar-18-19 11:41AM  
08:30AM  
Mar-12-19 12:53PM  
07:46AM  
07:30AM  
Mar-05-19 08:00AM  
Feb-05-19 08:30AM  
Dec-20-18 11:32AM  
Nov-28-18 08:00AM  
Nov-21-18 08:30AM  
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of schizophrenia. The company is also developing seltorexant that has completed Phase IIb clinical trial for treating insomnia and major depressive disorders; and MIN-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the roluperidone worldwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VAN HEEK G JANDirectorSep 10Buy2.977,00020,79020,333Sep 11 05:13 PM
Ahlholm Frederick WSVP, Chief Accounting OfficerMay 26Sale15.008,339125,0856,884May 27 04:43 PM
Race GeoffEVP, CFO & CBODec 17Sale7.105,82641,365205,044Dec 17 04:48 PM
Luthringer RemyCEODec 17Sale7.102,41217,12549,040Dec 17 04:46 PM
Ahlholm Frederick WSVP, Chief Accounting OfficerDec 17Sale7.101,55711,05515,223Dec 17 04:45 PM
Reilly Joseph H.SVP & Chief Operating OfficerDec 17Sale7.102,72419,34026,225Dec 17 04:44 PM
Russell Richard E.PresidentDec 12Sale7.423,11323,09833,770Dec 13 04:07 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.